Korea's ST Pharm completes new R&D hub for gene therapy

The new R&D center will house synthetic and oligo research institutes, allowing better collaboration among its scientists

Korea's ST Pharm completes new R&D hub for gene therapy
Ji-Hyun Lee 1
2023-03-03 16:03:13 bluesky@hankyung.com
Bio & Pharma

ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&D Innovation Center in Ansan City, Gyeonggi Province.

The 12-story center, which spans 5,166 square meters and cost 18 billion won ($14 million) to construct, opened on Feb. 3 after starting work in January last year.

The company said the center will house synthetic and oligo research institutes, which were previously located in Siwha and Banwol, both in Gyeonggi Province. This will allow better collaboration and research among its scientists.

The center will also host a quality control department to offer faster contract development and manufacturing (CDMO) services for oligonucleotide therapeutics.

A company official said the center will help the company enlist top researchers and boost its CDMO services, its main business area. He also said the center will serve as a key base for developing new drugs and creating new platforms for gene therapy.

Write to Ji-Hyun Lee at bluesky@hankyung.com
##ST Pharm R&D Center Dong-A Socio holdings #korea st-pharm r&d #stpharm r&d hub

ST Pharm exports $14.6 mn worth of drug ingredients to Europe

ST Pharm exports $14.6 mn worth of drug ingredients to Europe

ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth 18 billion won ($14.6 million) with a large European pharmaceutical company.With the company regaining sales of 200 billion won first in five year

Daewoong accelerates investment in CDMO business

Daewoong accelerates investment in CDMO business

Daewoong Bio Laboratory Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development and manufacturing (CDMO) business.In its stock exchange filing on Monday, Daewoong revealed that its subsidiary Daewoong Bio

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

South Korea's first homegrown COVID-19 vaccine, SKYCovione, produced by SK Bioscience South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanism while Samsung Biologics Co. remains lukewarm toward the eme
(* comment hide *}